Hydrofarm Holdings Group, Inc. — Q3 2023 Form 10-Q
Business and period: Unaudited results for the three and nine months ended September 30, 2023. Hydrofarm manufactures and distributes controlled-environment agriculture equipment and supplies, primarily in the United States and Canada.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement amounts are in millions except per-share data.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $54.2 | $74.2 | $179.4 | $283.0 |
| Gross profit / margin | $3.3 / 6.1% | $5.9 / 7.9% | $29.2 / 16.3% | $29.8 / 10.5% |
| Operating loss | $(16.2) | $(20.3) | $(38.3) | $(254.9) |
| Net loss | $(19.9) | $(23.5) | $(49.6) | $(250.1) |
| Diluted loss per share | $(0.44) | $(0.52) | $(1.09) | $(5.57) |
| Operating cash flow | Not stated separately | Not stated separately | $8.6 | $15.5 |
- At September 30, cash was $32.5 million, versus $21.3 million at December 31, 2022. Current assets were $133.9 million and current liabilities $35.4 million.
- Reported debt was $118.5 million, including $118.3 million of term-loan carrying value; the term loan’s outstanding principal was $122.8 million. No borrowings were outstanding on the revolving facility. Approximately $28 million was available to borrow before the 1.1x fixed-charge-coverage covenant would apply.
- Nine-month investing cash use was $4.1 million, mainly capital expenditures; financing cash provided was $6.6 million, including $8.6 million of sale-leaseback proceeds. Cash increased by $11.2 million over the period.
Material changes and management commentary
- Sales declined 27.0% year over year in Q3 and 36.6% in the first nine months. Management attributed the declines primarily to cannabis-industry oversupply and lower customer demand. Q3 sales volume fell 22% and price/product mix declined 5%; nine-month volume fell 34% and price/mix declined 2%.
- Q3 gross margin decreased to 6.1%, reflecting lower sales and approximately $7.4 million of restructuring charges, largely non-cash inventory markdowns. For the nine-month period, gross margin rose to 16.3% from 10.5%, partly because the 2022 comparison included substantially larger inventory reserves and related charges.
- SG&A decreased 25.4% in Q3 and 27.0% for the nine-month period, reflecting lower costs across several categories and restructuring measures. Interest expense increased, primarily because of higher variable rates on the term loan.
- The 2022 comparison included $192.3 million of impairment charges, principally goodwill impairment that reduced goodwill to zero. No impairment charges were recorded in the first nine months of 2023.
Outlook, risks, and unusual items
- Management expects cash, operating cash flows, and revolving-credit availability to support operations and obligations for the next 12 months, but cautions that future cash generation and borrowing availability are not assured.
- The second restructuring phase includes U.S. manufacturing consolidations. The company estimates additional charges may exceed $3.0 million over the next several quarters, including approximately $1.5 million of cash impact, and anticipates annualized savings of approximately $1.5 million. Actual costs and savings may differ; the company may not realize the expected savings.
- The term loan matures October 25, 2028, bears variable rates, and had an effective interest rate of 11.82% in Q3. Management estimated that a 100-basis-point rate increase would raise annual interest expense by about $1.1 million; the company does not currently hedge interest-rate exposure.
- The January 2023 Eugene-property transaction generated $8.6 million of proceeds but is accounted for as a failed sale-leaseback, with a 15-year lease and a corresponding financing liability. Any proceeds not reinvested as permitted may require an offer to prepay the term loan in 2024.
- Key risks include prolonged agricultural oversupply and weak grower economics, further inventory or asset impairments, restructuring execution and costs, variable-rate debt, supplier and supply-chain dependence, foreign-exchange movements, and financial-institution deposit exposure. The filing reports no known legal matters expected to have a material adverse effect. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether demand and sales volumes stabilize, particularly in cannabis-related markets, and whether pricing and product mix continue to weaken.
- Whether inventory markdowns, reserves, and restructuring charges recur, and whether stated annualized savings are achieved.
- Cash conversion and working-capital trends: nine-month operating cash flow was positive but below the prior-year period and depended partly on inventory reduction.
- Debt-service capacity, variable-rate exposure, revolver borrowing-base availability and covenant headroom, and the required treatment of sale-leaseback proceeds.
- Whether ongoing market conditions trigger further impairment testing or additional restructuring actions.